Connect with us

Politics

Lawmakers React To Sessions Anti-Marijuana Move

Published

on

A bipartisan collection of members of Congress and state officials are pushing back on U.S. Attorney General Jeff Sessions’s move to rescind Obama-era guidance that has generally allowed states to implement their own marijuana laws without federal interference.

Sen. Cory Gardner (R-CO):

Sen. Kirsten Gillibrand (D-NY):

Sen. Lisa Murkowski (R-AK):

Washington State Gov. Jay Inslee (D):

Colorado Gov. John Hickenlooper (D):

Massachusetts Cannabis Control Commission:

Congresswoman Nancy Pelosi (D-CA):

Sen. Chuck Schumer (D-NY):

Oregon Gov. Kate Brown (D):

Arkansas Gov. Asa Hutchinson (R):

Alaska Gov. Bill Walker (I):

“I remain committed to upholding the will of Alaskans on this issue, and maintaining our State’s sovereign rights to manage our own affairs while protecting federal interests.”

Colorado Attorney General Cynthia Coffman (R):

Congressman Denny Heck (D-WA):

Congressman Mike Coffman (R-CO):

Sen. Dan Sullivan (R-AK):

Today’s action by the Department of Justice — which contradicts previous statements by the President that this is an issue best left to the states, and adds new confusion and uncertainty for numerous states and communities — could be the impetus necessary for Congress to find a permanent legislative solution for states that have chosen to regulate the production, sale and use of marijuana. As we move forward, I will be examining new and existing legislative proposals and working to ensure the rights of Alaskans and the State of Alaska are protected.”

Congressman Don Young (R-AK):

“Today’s decision announced by the Department of Justice (DOJ) is a direct violation of states’ rights. Rolling back the Cole Memo without a responsible replacement to protect individuals and the states they live in is unacceptable.”

Congressman Carlos Curbelo (R-FL):

Sen. Bernie Sanders (I-VT):

Sen. Elizabeth Warren (D-MA):

Sen. Brian Schatz (D-HI):

Congressman Ted Lieu (D-CA):

Sen. Patrick Leahy (D-VT):

Sen. Jeanne Shaheen (D-NH):

Sen. Orrin Hatch (R-UT):

Congressman Jerrold Nadler (D-NY), Congresswoman Sheila Jackson Lee (D-TX) and Congressman Steve Cohen (D-TN):

“This change takes us in the wrong direction and is another step by the Trump Justice Department toward rolling back the sensible and more effective prosecution policies established by the Justice Department under President Obama. The Judiciary Committee should conduct hearings on these issues so that we may develop better strategies for preventing drug abuse and focusing the Justice Department’s efforts on those who pose the most serious threats to public safety.”

Congressman Dana Rohrabacher (R-CA):

Sen. Jeff Merkley (D-OR):

Massachusetts Gov. Charlie Baker (R):

North Dakota Gov. Doug Burgum (R):

We support states’ rights when deciding whether medical marijuana should be legalized, and North Dakota voters have spoken.”

Sen. Cory Booker (D-NJ):

Congressman Matt Gaetz (R-FL):

Pennsylvania Gov. Tom Wolf (D):

Congressman Rod Blum (R-IA):

California Attorney General Xavier Becerra (D):

Puerto Rico Gov. Ricardo Rosello (NPP):

Sen. Chris Van Hollen (D-MD):

Sen. Catherine Cortez Masto (D-NV):

Sen. Kamala Harris (D-CA):

Sen. Bob Casey (D-PA):

Sen. Ron Wyden (D-OR):

Sen. John Hoeven (R-ND):

States are really determining how this issue will be handled now and going forward, and I don’t think this policy decision will change that.”

Sen. Mark Warner (D-VA):

“It seems to be the absolute opposite direction from where our country’s headed.”

Congressman Keith Ellison (D-MN):

Congressman Kevin Cramer (R-ND):

Congress should act on this and make it clear that … this a states’ rights issue, that it should be up to states to determine whether they want to allow marijuana.”

Congresswoman Dina Titus (D-NV):

Congressman Jason Lewis (R-MN):

Congressman Scott Tipton (R-CO):

“The announcement by the Department of Justice is a drastic departure from the Attorney General’s previous commitment to Senator Cory Gardner during the confirmation process that he would uphold the Obama Administration’s treatment of marijuana enforcement and President Trump’s comments that he would leave it to the states. Furthermore it creates even greater confusion and uncertainty by leaving enforcement decisions up to federal prosecutors. The Department of Justice should provide guidance on enforcement of marijuana for states that have voted to legalize it. The people of Colorado voted to legalize marijuana in the state, and I am committed to defending the will of Coloradans.”

California Lt. Gov. Gavin Newsom (D):

Nevada Gov. Brian Sandoval (R):

Congressman Earl Blumenauer (D-OR):

Congresswoman Eleanor Holmes Norton (D-DC):

Congresswoman Barbara Lee (D-CA):

Congresswoman Tulsi Gabbard (D-HI):

Congressman Thomas Massie (R-KY):

Sen. Rand Paul (R-KY):

Sen. Dean Heller (R-NV):

Sen. Heidi Heitkamp (D-ND):

“I’m going to continue to follow this situation to see how it will impact our state, especially after North Dakotans made their voices heard and voted to legalize medical marijuana.”

Congressman Steve Cohen (D-TN):

Washington State Attorney General Bob Ferguson (D):

Sen. Patty Murray (D-WA):

Congressman Ro Khanna (D-CA):

Congressman Jared Polis (D-CO):

Sen. Chris Coons (D-DE):

Devoting our limited resources to prosecuting medical marijuana use that is permitted under Delaware state law is a poor allocation of federal time, money, and manpower that should be focused on more important things, such combating violent crime on our streets.”

Congressman Justin Amash (R-MI):

Congressman Beto O’Rourke (D-TX):

Congressman Adam Schiff (D-CA):

Congresswoman Chellie Pingree (D-ME):

Congressman Derek Kilmer (D-WA):

“This action by Attorney General Sessions would silence the voices of the majority of Washington state’s voters. No matter how you feel about the legalization of marijuana, this decision by the federal government to meddle in a state issue settled by public referendum is particularly troubling and would create tremendous uncertainty. It’s the wrong decision and is in direct conflict with the Attorney General’s long career of advocating for more autonomy for state and local governments.”

Congressman Seth Moulton (D-MA):

Congressman Darren Soto (D-FL):

Congressman Hank Johnson (D-GA):

Congressman Tim Walz (D-MN):

Congresswoman Nydia Velazquez (D-NY):

Congressman Hakeem Jeffries (D-NY):

Washington, D.C. Attorney General Karl Racine (D):

Nevada Attorney General Adam Laxalt (R):

Maryland Attorney General Brian Frosh (D):

Sen. Michael Bennet (D-CO):

Congressman Mark Takano (D-CA):

Congresswoman Pramila Jayapal (D-WA):

Connecticut Gov. Dannel Malloy (D):

“Especially during the midst of a national opioid crisis, medical marijuana provides an important alternative to opioids and is counted on for relief by 22,000 Connecticut residents. Rather than diverting critical federal resources and infringing on the will of the American people, Attorney General Sessions would do well to take a leaf out of Connecticut’s book, where our marijuana policies have allowed law enforcement professionals to focus on reducing violent crime, with demonstrated success. We will continue to follow Connecticut law regarding marijuana policy despite this short-sighted decision.”

Congresswoman Suzan DelBene (D-WA):

Congresswoman Suzanne Bonamici (D-OR):

Congresswoman Julia Brownley (D-CA):

Congressman Mike Thompson (D-CA):

Congressman Ed Perlmutter (D-CO):

Congressman Joe Crowley (D-NY):

Congressman Ryan Cosetllo (R-PA):

Congressman Ruben Gallego (D-AZ):

Massachusetts Attorney General Maura Healey (D):

Congresswoman Jacky Rosen (D-NV):

Congressman Peter Welch (D-VT):

Congressman Tom Garrett (R-VA):

Congresswoman Colleen Hanabusa (D-HI):

Congressman Adam Lowenthal (D-CA):

Congressman John Delaney (D-MD):

“The Cole Memo provided clear guidance to an otherwise conflicting situation. Revoking the Cole Memo will restore that confusion and undermines the will of the voters in several states.”

Congressman Ruben Kihuen (D-NV):

Congressman Adam Smith (D-WA):

Colorado Senate Democrats:

This post will be updated as more reactions come in.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Tom Angell is the editor of Marijuana Moment. A 15-year veteran in the cannabis law reform movement, he covers the policy and politics of marijuana. Separately, he founded the nonprofit Marijuana Majority. Previously he reported for Marijuana.com and MassRoots, and handled media relations and campaigns for Law Enforcement Against Prohibition and Students for Sensible Drug Policy. (Organization citations are for identification only and do not constitute an endorsement or partnership.)

Politics

Feds Award $3 Million In Grants To Study Marijuana Ingredients As Alternatives To Opioids

Published

on

The federal government has awarded $3 million in grants for research into the therapeutic benefits of ingredients in marijuana other than THC, emphasizing their potential as alternatives to prescription opioids.

In a notice published on Thursday, the National Institutes of Health (NIH) explained why the studies were necessary and listed grant recipients and the subjects they will investigate. That includes research into the use of CBD for arthritis pain, which will be led by New York University School of Medicine.

“The treatment of chronic pain has relied heavily on opioids, despite their potential for addiction and overdose and the fact that they often don’t work well when used on a long-term basis,” Helene Langevin, director of the National Center for Complementary and Integrative Health (NCCIH), said in a press release. “There’s an urgent need for more effective and safer options.”

A total of nine grants were issued, with NIH stating that the funds will help identify alternative treatment options for pain and provide information about the impact of consuming cannabis compounds such as CBD and other lesser-known cannabinoids as well as terpenes found in the plant.

“The cannabis plant contains more than 110 cannabinoids and 120 terpenes, but the only compound that’s been studied extensively is THC,” the press release said.

But while THC is known to treat certain forms of pain, NIH is concerned that its intoxicating effects limit its medical applicability.

“THC may help relieve pain, but its value as an analgesic is limited by its psychoactive effects and abuse potential,” David Shurtleff, deputy director of NCCIH, said. “These new projects will investigate substances from cannabis that don’t have THC’s disadvantages, looking at their basic biological activity and their potential mechanisms of action as pain relievers.”

NIH first announced that it would be issuing grants for studies into minor cannabinoids and terpenes last year.

Federal health agencies aren’t the only institutions interested in learning about marijuana compounds other than THC. On Wednesday, a Senate committee issued a spending report that called for research into CBD and CBG while also criticizing the federal drug scheduling system for inhibiting such research.

Read descriptions of the federal cannabinoid and terpene research grant awards below:

Mechanism and Optimization of CBD-Mediated Analgesic Effects; Boston Children’s Hospital, Boston,; Zhigang He, Ph.D., B.M., and Juan Hong Wang, Ph.D. This project will investigate how the pain-relieving effects of cannabidiol (CBD) and other minor cannabinoids may be modulated by the activity of potassium-chloride cotransporter 2 (KCC2), a chloride extruder expressed in most neurons. (Grant 1R01AT010779)

Neuroimmune Mechanisms of Minor Cannabinoids in Inflammatory and Neuropathic Pain; University of California, San Francisco; Judith Hellman, M.D., and Mark A. Schumacher, M.D., Ph.D. This project will explore the effects of minor cannabinoids on inflammatory and neuropathic pain in vitro and in vivo, focusing on the interactions of the cannabinoids with the peripheral receptor called TRPV1 and a cannabinoid receptor, CB1R. (Grant 1R01AT010757)

Minor Cannabinoids and Terpenes: Preclinical Evaluation as Analgesics; Research Triangle Institute, Research Triangle Park, North Carolina; Jenny L. Wiley, Ph.D. This project will evaluate purified biosynthesized minor cannabinoids and selected terpenes alone and in planned combinations to determine their potential efficacy as pain relievers against acute thermal, inflammatory, neuropathic, and visceral pain. (Grant 1R01AT010773)

Identifying the Mechanisms of Action for CBD on Chronic Arthritis Pain; New York University School of Medicine, New York City; Yu-Shin Ding, Ph.D. This project will use neuroimaging studies and behavioral assessments to investigate the mechanisms of action of CBD in the modulation of chronic pain associated with osteoarthritis in a mouse model. (Grant 1R21AT010771)

Synthetic Biology for the Chemogenetic Manipulation of Pain Pathways; University of Texas, Austin; Andrew Ellington, Ph.D. This project will use a novel method to evolve individual variants of cannabinoid receptor type 2 (CB2) that interact with high affinity with minor cannabinoids and evaluate the new variants in a mouse model of pain. (Grant 1R21AT010777)

Exploring the Mechanisms Underlying the Analgesic Effect of Cannabidiol Using Proton Magnetic Resonance Spectroscopy; University of Utah, Salt Lake City; Deborah A. Yurgelun-Todd, Ph.D. This project will use proton magnetic resonance spectroscopy (1H-MRS) to evaluate changes in brain chemistry in critical pain-processing regions after short-term administration of a cannabis extract enriched in CBD. (Grant 1R21AT010736)

Mechanistic Studies of Analgesic Effects of Terpene Enriched Extracts from Hops; Emory University, Atlanta; Cassandra L. Quave, Ph.D. This project will take a multidisciplinary approach to investigate the analgesic effects of terpenes from Humulus lupulus (hops), a plant that is closely related to cannabis and has a very similar terpene profile. (Grant 1R21AT010774)

Systematic Investigation of Rare Cannabinoids With Pain Receptors; University of Illinois at Urbana-Champaign; David Sarlah, Ph.D. This project involves synthesizing several classes of rare phytocannabinoids, systematically evaluating their anti-inflammatory potential, and examining the effects of the compounds with the strongest anti-inflammatory potential on the major receptors involved in pain sensation. (Grant 1R21AT010761)

Analgesic efficacy of single and combined minor cannabinoids and terpenes; Temple University, Philadelphia; Sara J. Ward, Ph.D. This project will use rodent models of pain to evaluate the effects of four biologically active components of cannabis that may act synergistically to protect against pain development and to assess the interactions of these four substances with morphine. (Grant 1R01AT010778)

Senate Report Slams Drug Scheduling System For Blocking Marijuana Research

 

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Beto O’Rourke Proposes Drug War Reparations Funded By Marijuana Taxes

Published

on

Marijuana would not only be legalized under a plan proposed on Thursday by Democratic presidential candidate Beto O’Rourke, but cannabis tax revenue would be used to directly repay formerly incarcerated people through a new “Drug War Justice Grant” program.

Unlike other contenders who have come around to supporting marijuana legalization in just the past couple of years, the former Texas congressman has long called for ending prohibition—and his new plan in many respects goes further than those rolled out by other campaigns.

Please visit Forbes to read the rest of this piece.

(Marijuana Moment’s editor provides some content to Forbes via a temporary exclusive publishing license arrangement.)

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Support Grows For Marijuana Legalization Bill In Colombia

Published

on

Colombia’s legislature will soon take up a bill to legalize and regulate the production and consumption of marijuana for adults.

The legislation, which is being filed by Sen. Gustavo Bolivar of the opposition Colombia Humana party, seeks to end prohibition as a means of curtailing crime and supporting a public health-focused approach to drug policy.

Bolivar, an author who has written several books centered on drug trafficking, has characterized the bill as being about “regularization, not legalization,” but it would provide for legal sales to adults with restrictions similar to those imposed for tobacco and alcohol. There would be penalties for selling to underage individuals and smoking wouldn’t be permitted in public spaces.

The senator pointed to Uruguay, Canada and states in the U.S. as regulatory models for legalization.

“It has been proven that crime levels are lowered and public health is improved,” he said, according to Colombia Reports.

Sen. Alberto Castilla Salazar of the leftist Polo Democrático party said that his coalition supports the reform measure.

“Colombia must overcome prohibitionism and break the ties of illegal groups with the control of cannabis, so that it is the State that regulates, defines the forms and understands consumption as a public health problem,” he said on Tuesday.

Sen. Julián Gallo Cubillos of the FARC party said his coalition supports the legislation and that it represents “a new way to fight the scourge of drug trafficking.”

The proposal has also garnered the support of former President Juan Manuel Santos, who has been an outspoken advocate for ending the war on drugs. His Liberal party could make or break the legislation depending on where members fall.

While left and center-left lawmakers seem largely united around legalizing marijuana, the issue will likely face resistance from President Ivan Duque, who last year signed a decree banning low-level possession of cannabis and cocaine despite court rulings that such activity is permissible.

As Colombia Reports noted, however, Duque’s far-right Democratic Center party is in the minority.

“We’ll have to see how many senators are left to former president Juan Manuel Santos and see how public opinion receives the idea that marijuana can be consumed in public spaces,” Sen. Paloma Valencia, a member of the president’s party, said.

If the country does opt to pursue a regulated cannabis program, it will join Mexico, where lawmakers are readying legislation to legalize marijuana for adult use following a Supreme Court ruling establishing that a ban on possession and cultivation for personal use is unconstitutional.

Former White House Drug Czar Offers Marijuana Legalization Advice To Mexico

Photo courtesy of Brian Shamblen.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Stay Up To The Moment

Marijuana News In Your Inbox


Support Marijuana Moment

Marijuana News In Your Inbox

Do NOT follow this link or you will be banned from the site!